StatLab Medical Products Expands McKinney, Texas, Operations Complex
02/26/2021
According to company officials, this investment highlights StatLab’s continued growth and commitment to meeting the needs of the anatomic pathology and molecular diagnostic markets.
“A dedicated distribution center allows StatLab to triple the amount of temperature-controlled and flammable storage space compared to our existing facility. This means we can keep more of these products in stock to support supply chain stability for our customers,” said COO Kamron Keyes.
Founded in 1976, StatLab Medical Products is leading the way in development and manufacturing of high-quality histology, cytology and immunohistochemistry diagnostic products. The company partners with anatomic pathology laboratories to provide easy access to over 3,500 high-quality diagnostic products and equipment at excellent prices, delivered with expert support.
“We’ve outgrown the available manufacturing space in our current ISO-13485 facility, added Keyes. “Converting the existing warehouse space to manufacturing operations means we can work more efficiently, grow our teams, and increase production capacity, continuous improvement in action.”
Project Announcements
Cascades Expands Eau Claire, Wisconsin, Operations
12/25/2025
P.C. Campana Plans Vicksburg, Mississippi, Production Operations
12/25/2025
Midwest Equipment Manufacturing Expands Maysville, Kentucky, Operations
12/25/2025
Stord Expands Hebron, Kentucky, Warehouse Operations
12/25/2025
Edelweiss Dairy Expands Freedom, New York, Operations
12/24/2025
Hut 8 Plans West Feliciana, Louisiana, Data Center Operations
12/24/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
Tariff Shockwaves Hit the Industrial Sector
Q4 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025